milkenmike
Posted - 1 day ago
$ZEAL $ELAB
A lot of new players entering the obesity space. There’s lots of pitfalls with the current class of drugs. This is one to watch; initial clinical results are promising. Adding a myostatin blocker seems like a prudent approach. Ask any plastic surgeon, ozempic face is a huge problem that needs a fix and the aesthetic issues are really the tip of the overall health picture. https://finance.yahoo.com/news/elevai-labs-acquires-exclusive-license-130000444.html
BTECHINV
Posted - 04/24/24
$ALT $xbi Validating the long hypothesized medical science view highlighted in Nature Reviews over a decade ago could make Pemvidutide THE GLP-1 leader in Obesity as no one does Glucagon agonism better than PEMVI in my opinion. Once PEMVI (and Survo $zeal) hit the market, very tough for other GCGR/GLP-1 candidates to follow/differentiate. Company alluded to energy expenditure in March ER call. (GLP-1 agonism alone does NOT provide this effect.) ..."We think this would also represent a fundamental effect of glucagon on intermediary metabolism and energy expenditure that could continue in the future basically changing the metabolic balance and having in that score, real differentiation from the GLP-1s and the GIPs. We don't have that data at this point. It certainly would be of great interest to study this going forward, and it's something that we're strongly considering in our Phase III program." Long Altimmune (GLP-1/GlucagonR), not medical/investment advice.
Neo_the_Cat
Posted - 03/05/24
With the hype surrounding viking, it's no longer useful to compare its valuation to $alt and derive any meaningful insight. A far more logical proxy is $zeal. Survo and Pemvi are both glucagon based and in similar clinical stage. While Survo is about 10 months ahead in phase 3. Pemvi has a lower discontinuation rate and more glucagon focused, therefore in theory more effective against NASH. Not to say share prices should trade in lock step, but the mkt. cap range of Zealand should be instructive towards the intrinsic value of Altimmune. Right now, Zealand is trading near ATH $6b USD
Ninja_Tradez
Posted - 2 months ago
📢 $ZEAL - Zealand Pharma to Participate in TD Cowen's 44th Annual Health Care Conference https://newsfilter.io/a/0d28fdba61eeb32d5808da0528ccb201
Jstockdaddy
Posted - 02/28/24
$OCEA when we get PR results this is going to make moves like $VKTX $TPST $ZEAL type moves
Meltingflame
Posted - 02/27/24
$OPK Completed mid-stage trials. Low key!! $ALT $VKTX $ZEAL See screenshot below on rundown of the challengers. Opko is the silent one with the same MoA as Pemvidutide from ALT. Putting you on to the next game. OPK reports ER tonight. Ps: sorry for cross-tagging. But hopefully you see it's in good spirits.
Szepen
Posted - 02/27/24
$ALT $VKTX $ZEAL Right👌
Wen7BNeverRightNicholson
Posted - 02/27/24
$ALT $VKTX $ZEAL by the way thank you Zealand and thank you Viking! Zealand shows the World that our drug has enormous potential and Viking shows the World that a $7B valuation for Alt is a bargain! 😘😘😘 Love
speakmannameonlyonce
Posted - 02/26/24
$MDGL thoughts on $zeal NASH data out this morning? PH2.
Power2k
Posted - 01/29/24
$ZEAL Is this on NASDAQ?
Ro_Patel
Posted - 01/23/24
Danish biotech group $ZEAL Pharma is developing an alternative obesity treatment to compete
Early-stage trials of Zealand drug suggests it could achieve similar weight loss with reduced side effects of vomiting, nausea & constipation associated with GLP-1s
German pharma group Boehringer Ingelheim & Zealand are also testing their weight loss treatment survodutide, a GLP-1 or glucagon-like peptide 1 agonist drug similar to Wegovy, for its effectiveness in tackling NASH, a chronic liver disease that is estimated to affect up to 6.5% of US adults.
Zealand is also developing alternative treatments — based on a hormone called amylin — that promotes a feeling of fullness after eating, rather than suppressing appetite.
$LLY $NVO $PFE
STCKPRO
Posted - 01/19/24
$ZEAL NEW ARTICLE : Zealand Pharma major shareholder announcement: J O Hambro Capital Management https://stck.pro/news/ZEAL/73176012/
STCKPRO
Posted - 01/17/24
$ZEAL NEW ARTICLE : Zealand Pharma major shareholder announcement: J O Hambro Capital Management https://www.stck.pro/news/ZEAL/72972039/
STCKPRO
Posted - 01/12/24
$ZEAL NEW ARTICLE : Zealand Pharma completes registration of capital increase https://www.stck.pro/news/ZEAL/72441648/
STCKPRO
Posted - 4 months ago
$ZEAL NEW ARTICLE : Zealand Pharma to participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference on January 4th https://www.stck.pro/news/ZEAL/71397711/
DonCorleone77
Posted - 12/24/23
$ZEAL 2 of 2 - Zealand says FDA issued CRL for CHI for up to 3 weeks of dosing ...."Based on our understanding of the FDA's position, we remain confident in the potential for dasiglucagon to help children and their families affected by congenital hyperinsulinism." Zealand expects to resubmit the NDA for dasiglucagon for CHI for up to three weeks of dosing in the first half of 2024 contingent on successful reinspection of the third-party manufacturing facility.
DonCorleone77
Posted - 12/24/23
$ZEAL 1 of 2 - Zealand says FDA issued CRL for CHI for up to 3 weeks of dosing Zealand Pharma announced that the U.S. Food and Drug Administration has issued a Complete Response Letter for Part 1 of the New Drug Application for dasiglucagon for the prevention and treatment of hypoglycemia in pediatric patients 7 days of age and older with congenital hyperinsulinism, or CHI, for up to 3 weeks of dosing. The CRL is related to deficiencies identified following an inspection at a third-party contract manufacturing facility. These deficiencies are not specific to dasiglucagon. The CRL did not state any concerns about the clinical data package or safety of dasiglucagon....
Princeb
Posted - 12/22/23
$ZEAL is this tradable in US?? What ticker?? The OTC?
SM095
Posted - 12/22/23
$ZEAL Zealand Pharma submits New Drug Application to the US FDA for glepaglutide in short bowel syndrome
TangoToEvora
Posted - 12/19/23
$ZEAL no human being without bots here?
STCKPRO
Posted - 5 months ago
$ZEAL NEW ARTICLE : Zealand Pharma to highlight obesity pipeline at R&D Event on December 5 https://www.stck.pro/news/ZEAL/69314709/
STCKPRO
Posted - 5 months ago
$ZEAL NEW ARTICLE : Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons https://www.stck.pro/news/ZEAL/69312957/
STCKPRO
Posted - 11/30/23
$ZEAL NEW ARTICLE : Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers https://www.stck.pro/news/ZEAL/68947479/
cctranscripts
Posted - 11/10/23
Worth checking out CEO questions suggested as to $ZEAL call (transcript) https://conferencecalltranscripts.com/summary/?id=534633&pr=true
STCKPRO
Posted - 11/09/23
$ZEAL NEW ARTICLE : Zealand Pharma Announces Financial Results for the First Nine Months of 2023 https://www.stck.pro/news/ZEAL/66940603/
STCKPRO
Posted - 11/07/23
$ZEAL NEW ARTICLE : Zealand Pharma to participate in the Jefferies London Healthcare Conference in November 2023 https://www.stck.pro/news/ZEAL/66767587/
STCKPRO
Posted - 10/17/23
$ZEAL NEW ARTICLE : Zealand Pharma presents data for amylin analog ZP8396 at ObesityWeek https://www.stck.pro/news/ZEAL/64933406/
Quantisnow
Posted - 10/05/23
$ZEAL 📰 Phase III studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease
https://quantisnow.com/i/5005667?utm_source=stocktwits
45 seconds delayed.
STCKPRO
Posted - 08/31/23
$ZEAL NEW ARTICLE : Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons https://www.stck.pro/news/ZEAL/60340575/
